Loading clinical trials...
Loading clinical trials...
Serum Pepsinogen After Helicobacter Pylori Eradication for the Gastric Cancer Prevention
Helicobacter pylori has been recognized as a major pathogen in gastric carcinogenesis. Current guidelines recommend the H. pylori "test-and-treat" strategy for the purpose of primary and secondary gastric cancer prevention. Considering the "point of no return" theory, however, H. pylori eradication cannot reduce the risk of gastric cancer in subjects with gastric atrophy and intestinal metaplasia. The intragastric hypoacidic environment is associated with the risk of intestinal-type gastric cancer development. Recently, the secretory ability of the stomach can be measured using the serum pepsinogen (PG) assay.
This study aimed to evaluate the change of serum PGs after H. pylori eradication success and identify the optimal timing of eradication.
Age
20 - 70 years
Sex
ALL
Healthy Volunteers
No
Digestive Disease Center, Soonchunhyang University Hospital
Seoul, South Korea
Start Date
March 15, 2019
Primary Completion Date
March 15, 2020
Completion Date
May 31, 2020
Last Updated
July 27, 2020
100
ACTUAL participants
Lead Sponsor
Soonchunhyang University Hospital
NCT06977841
NCT05191888
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02776371